drugset / Trial / NCT02184260

Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke

NCT02184260

Phase 4 Terminated 58 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Clinical efficacy and safety of Metamizole 2 g i.v. versus placebo, as antithermic therapy in the acute phase of ischemic stroke.

Timeline

Start
1998-12
Primary completion
2002-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Metamizole Unknown 2 g Intravenous

Indications